The New Paper

March 22, 2021

AstraZeneca releases US trial data for coronavirus vaccine

AstraZeneca announced that its coronavirus vaccine is 79% effective in preventing symptomatic cases and 100% effective against severe cases and hospitalization based on late-stage US clinical trials. The study also found no increased risk of blood clotting (following concerns in several European countries earlier this month). The company plans to request emergency use authorization from the FDA in the coming weeks.
This story is from the March 22, 2021 edition of The New Paper – a clear, concise daily briefing that makes fact-first news easy to consume. Try it today.